leisure time -WSS

leisure time

author：explore 2025-09-06 04:35:48 - browse：1

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Prime Medicine says its gene editing passes test in monkeys

Wikipedia

WSS

All of Us, NIH's precision medicine initiative, gets a big boost

Diversity in clinical trials starts with building trust, experts say

Readout LOUD podcast: ESMO highlights & Roivant's big deal

How to convince healthy people to buy insurance

Cholera vaccine supply gets boost as demand surges globally

Cholera vaccine supply gets boost as demand surges globally

focus

leisure time

explore

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Bird flu in milk supply is likely coming from asymptomatic cows

Duchenne breakthrough therapy leaves behind pioneering families

Gene therapy’s promise and the high cost of hope

United colonoscopy coverage change 'may cost lives,' doctors say

Gene therapy’s promise and the high cost of hope

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Q&A: Jennifer Adair on making gene therapy available globally

The high cost of giving birth even with insurance

Brain injuries and the importance of a second opinion

entertainment

Element Biosciences CEO lays out genome sequencing strategy

Getting Alzheimer's drug Leqembi to patients can be a challenge

Dogs on Prozac: What pet anti

Getting Alzheimer's drug Leqembi to patients can be a challenge

After Sarepta trial failure, Duchenne families brace for more debate

Medical bills so high, Medicare adding extra digits to claim forms

leisure time

Wikipedia

focus

explore